Western blot analysis of tumor samples from mice sacrificed on day 14, after 1 week of treatment, demonstrated that cetuximab plus saracatinib efficiently interferes with EGFR-dependent signal transduction by reducing phosphorylation/activation of EGFR, Src, Akt and MAPK. This evidence concerns the gene EGFR and neoplasm.